

## Léčebné postupy u metastatického karcinomu ledvin

MICHAEL STAEHLER, KARL ROHRMANN, ALEXANDER BACHMANN, DIRK ZAAK, CHRISTIAN G. STIEF a MICHAEL SIEBELS

Department of Urology, Klinikum Grosshadern, Ludwig Maximilians University Munich, Germany

### LITERATURA

- 1 Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973–92. *Eur J Cancer Prev* 2002; 11: 171–8
- 2 Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. *JAMA* 1999; 281: 1628–31
- 3 Jemal A, Tiwari RC, Murray T *et al.* Cancer statistics, 2004. *CA Cancer J Clin* 2004; 54: 8–29
- 4 Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. *Urol Clin North Am* 2003; 30: 843–52
- 5 Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Current treatment options. *Oncology* 2003; 4: 385–90
- 6 Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. *Semin Oncol* 2000; 27: 234–9
- 7 Atzpodi J, Kirchner H, Jonas U *et al.* Interleukin-2- and interferon alfa-2abased immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *J Clin Oncol* 2004; 22: 1188–94
- 8 Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. *J Clin Oncol* 2000; 18: 1928–35
- 9 Negrier S, Douillard JY, Gomez F, Lasset C, Chevreau C, Escudier B. [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]. *Prog Urol* 2002; 12: 213–8
- 10 Fishman M, Antonia S. Novel therapies for renal cell carcinoma – an update. *Expert Opin Invest Drugs* 2003; 12: 593–609
- 11 Flanigan RC, Salmon SE, Blumenstein BA *et al.* Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med* 2001; 345: 1655–9
- 12 Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renalcell carcinoma: a randomised trial. *Lancet* 2001; 358: 966–70
- 13 Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. *J Urol* 1994; 152: 1399–403
- 14 Siemer S, Lehmann J, Kamradt J *et al.* Adrenal metastases in 1635 patients with renal cell carcinoma. outcome and indication for adrenalectomy. *J Urol* 2004; 171: 2155–9
- 15 Kobayashi T, Nakamura E, Yamamoto S *et al.* Low incidence of ipsilateral adrenal involvement and recurrences in patients with renal cell carcinoma undergoing radical nephrectomy: a retrospective analysis of 393 patients. *Urology* 2003; 62: 40–5
- 16 Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML. Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. *BJU Int* 2003; 91: 775–9
- 17 Alves A, Adam R, Majno P *et al.* Hepatic resection for metastatic renal tumors: is it worthwhile? *Ann Surg Oncol* 2003; 10: 705–10
- 18 Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. *J Clin Oncol* 1998; 16: 2261–6
- 19 Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. *Ann Surg Oncol* 1994; 1: 345–52
- 20 O'Dea MJ, Zincke H, Utz DC, Bernatz PE. The treatment of renal cell carcinoma with solitary metastasis. *J Urol* 1978; 120: 540–2
- 21 Volkmer BG, Gschwend JE. [Value of metastases surgery in metastatic renal cell carcinoma]. *Urologe A* 2002; 41: 225–30

- 22 **Itano NB, Blute ML, Spotts B, Zincke H.** Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. *J Urol* 2000; **164**: 322–5
- 23 **Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP.** Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. *J Urol* 2002; **167**: 1630–3
- 24 **Wiesner C, Jakse G, Rohde D.** Therapy of local recurrence of renal cell carcinoma. *Oncol Rep* 2002; **9**: 189–92
- 25 **Ghavamian R, Klein KA, Stephens DH et al.** Renal cell carcinoma metastatic to the pancreas: clinical and adiological features. *Mayo Clin Proc* 2000; **75**: 581–5
- 26 **Law CH, Wei AC, Hanna SS et al.** Pancreatic resection for metastatic renal cell carcinoma. Presentation, treatment, and outcome. *Ann Surg Oncol* 2003; **10**: 922–6
- 27 **Sohn TA, Yeo CJ, Cameron JL, Nakeeb A, Lillemoe KD.** Renal cell carcinoma metastatic to the pancreas. results of surgical management. *J Gastrointest Surg* 2001; **5**: 346–51
- 28 **Badalament RA, Gluck RW, Wong GY et al.** Surgical treatment of brain metastases from renal cell carcinoma. *Urology* 1990; **36**: 112–7
- 29 **Blom JH, van Poppel H, Marechal JM et al.** Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. *Eur Urol* 1999; **36**: 570–5
- 30 **Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H.** A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. *J Urol* 2004; **172**: 465–9
- 31 **Pantuck AJ, Zisman A, Dorey F et al.** Renal cell carcinoma with retroperitoneal lymph nodes. role of lymph node dissection. *J Urol* 2003; **169**: 2076–83
- 32 **Pantuck AJ, Zisman A, Dorey F et al.** Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. *Cancer* 2003; **97**: 2995–3002
- 33 **Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H.** Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. *Ann Thorac Surg* 2002; **74**: 1653–7
- 34 **Piltz S, Meimarakis G, Wichmann M, Oberneder R, Jauch KW, Furst H.** [Surgical treatment of pulmonary metastases from renal cancer]. *Urologe A* 2003; **42**: 1230–7
- 35 **Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H.** Long-term results after pulmonary resection of renal cell carcinoma metastases. *Ann Thorac Surg* 2002; **73**: 1082–7
- 36 **Goering JD, Mahvi DM, Niederhuber JE, Chicks D, Rikkers LF.** Cryoablation and liver resection for noncolorectal liver metastases. *Am J Surg* 2002; **183**: 384–9
- 37 **Lin CH, Moinzadeh A, Ramani AP, Gill IS.** Histopathologic confirmation of complete cancer cell kill in excised specimens after renal cryotherapy. *Urology* 2004; **64**: 590
- 38 **Lowry PS, Nakada SY.** Renal cryotherapy: 2003 clinical status. *Curr Opin Urol* 2003; **13**: 193–7
- 39 **Chin JL, Pautler SE.** New technologies for ablation of small renal tumors: current status. *Can J Urol* 2002; **9**: 1576–82
- 40 **de Baere T, Risse O, Kuoch V et al.** Adverse events during radiofrequency treatment of 582 hepatic tumors. *AJR Am J Roentgenol* 2003; **181**: 695–700
- 41 **Gervais DA, Arellano RS, Mueller PR.** Percutaneous radiofrequency ablation of nodal metastases. *Cardiovasc Intervent Radiol* 2002; **25**: 547–9
- 42 **Hinshaw JL, Lee FT Jr.** Image-guided ablation of renal cell carcinoma. *Magn Reson Imaging Clin N Am* 2004; **12**: 429–47
- 43 **Lui KW, Gervais DA, Arellano RA, Mueller PR.** Radiofrequency ablation of renal cell carcinoma. *Clin Radiol* 2003; **58**: 905–13
- 44 **Rhim H, Dodd GD, Chintapalli KN et al.** Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. *Radiographics* 2004; **24**: 41–52
- 45 **Tepel J, Hinz S, Klomp HJ, Kapischke M, Kremer B.** Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. *Eur J Surg Oncol* 2004; **30**: 551–5
- 46 **Durr HR, Maier M, Pfahler M, Baur A, Refior HJ.** Surgical treatment of osseous metastases in patients with renal cell carcinoma. *Clin Orthop* 1999; **367**: 283–90
- 47 **Durr HR, Refior HJ.** [Prognosis of skeletal metastases]. *Orthopade* 1998; **27**: 294–300
- 48 **Goldman FD, Dayton PD, Hanson CJ.** Renal cell carcinoma and osseous metastases. Case report and literature review. *J Am Podiatr Med Assoc* 1989; **79**: 618–25
- 49 **Jung ST, Ghert MA, Harrelson JM, Scully SP.** Treatment of osseous metastases in patients with renal cell carcinoma. *Clin Orthop* 2003; **409**: 223–31

- 50 Brinkmann OA, Bruns F, Prott FJ, Hertle L. Possible synergy of radiotherapy and chemoimmunotherapy in metastatic renal cell carcinoma (RCC). *Anticancer Res* 1999; **19**: 1583-7
- 51 Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. *Cancer* 1998; **83**: 2548-53
- 52 Maor MH, Frias AE, Oswald MJ. Palliative radiotherapy for brain metastases in renal carcinoma. *Cancer* 1988; **62**: 1912-7
- 53 Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. *Urology* 1996; **47**: 187-93
- 54 Hoskin PJ, Crow J, Ford HT. The influence of extent and local management on the outcome of radiotherapy for brain metastases. *Int J Radiat Oncol Biol Phys* 1990; **19**: 111-5
- 55 Posner JB. Management of brain metastases. *Rev Neurol (Paris)* 1992; **148**: 477-87
- 56 Andrews DW, Scott CB, Sperduto PW *et al*. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases. phase III results of the RTOG 9508 randomised trial. *Lancet* 2004; **363**: 1665-72
- 57 Siebels M, Oberneder R, Buchner A *et al*. [Ambulatory radiosurgery in cerebral metastatic renal cell carcinoma. 5-year outcome in 58 patients]. *Urologe A* 2002; **41**: 482-8
- 58 Wowra B, Siebels M, Muacevic A, Kreth FW, Mack A, Hofstetter A. Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. *J Neurosurg* 2002; **97**: 785-93
- 59 Amato RJ. Chemotherapy for renal cell carcinoma. *Semin Oncol* 2000; **27**: 177-86
- 60 Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-93. *Semin Oncol* 1995; **22**: 42-60
- 61 Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. *Urol Clin North Am* 1993; **20**: 303-21
- 62 Bennouna J, Delva R, Gomez F *et al*. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. *Oncology* 2003; **64**: 25-7
- 63 Fizazi K, Rolland F, Chevreau C *et al*. A phase II study of irinotecan in patients with advanced renal cell carcinoma. *Cancer* 2003; **98**: 61-5
- 64 De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a phase II study in patients with advanced renal cancer. *Cancer Chemother Pharmacol* 1996; **37**: 491-5
- 65 Rohde D, De Mulder PH, Weissbach L, Osieka R, Blatter J, Jakse G. Experimental and clinical efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. *Oncology* 1996; **53**: 476-81
- 66 Stadler WM, Huo D, George C *et al*. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. *J Urol* 2003; **170**: 1141-5
- 67 Brunsch U, Heinrich B, Kaye SB *et al*. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. *Eur J Cancer* 1994; **30A**: 1064-7
- 68 Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. *J Clin Oncol* 2000; **18**: 2419-26
- 69 Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. *Cancer* 2004; **101**: 1545-51
- 70 Douglas ML, Reid JL, Hii SI, Jonsson JR, Nicol DL. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. *BJU Int* 2002; **89**: 591-5
- 71 Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. *Ann Oncol* 2004; **15**: 1151-60
- 72 Gordon MS. Novel antiangiogenic therapies for renal cell cancer. *Clin Cancer Res* 2004; **10**: 6377S-81S
- 73 Amato RJ. Thalidomide therapy for renal cell carcinoma. *Crit Rev Oncol Hematol* 2003; **46** (Suppl): S59-65
- 74 Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. *Am J Med* 2004; **117**: 508-15
- 75 Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. *J Support Oncol* 2003; **1**: 194-205
- 76 Clark PE, Hall MC, Miller A *et al*. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. *Urology* 2004; **63**: 1061-5
- 77 Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. *J Immunother* 2004; **27**: 259-64
- 78 Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. Interferon alfa-

- 2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. *J Clin Oncol* 2003; **21**: 3770–6
- 79 **Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L.** A phase II study of thalidomide in advanced metastatic renal cell carcinoma. *Invest New Drugs* 2002; **20**: 389–93
- 80 **Schwartz LH, Mazumdar M, Wang L et al.** Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. *Cancer* 2003; **98**: 1611–9
- 81 **Motzer RJ, Berg W, Ginsberg M et al.** Phase II trial of thalidomide for patients with advanced renal cell carcinoma. *J Clin Oncol* 2002; **20**: 302–6
- 82 **Wyczolkowski M, Klima W, Bieda W, Walas K.** Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. *Urol Int* 2001; **66**: 119–20
- 83 **Young RC.** Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? *N Engl J Med* 1998; **338**: 1305–6
- 84 **Feldman JD, Jacobs SC.** Late development of renal carcinoma in allograft kidney. *J Urol* 1992; **148**: 395–7
- 85 **Siebels M, Theodorakis J, Liedl B, Schneede P, Hofstetter A.** Large de novo renal cell carcinoma in a 10-year-old transplanted kidney: successful organ-preserving therapy. *Transplantation* 2000; **69**: 677–9
- 86 **Williams JC, Merguerian PA, Schned AR, Morrison PM.** Acquired renal cystic disease and renal cell carcinoma in an allograft kidney. *J Urol* 1995; **153**: 395–6
- 87 **Ognibene FP, Rosenberg SA, Lotze M et al.** Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. *Chest* 1988; **94**: 750–4
- 88 **Segura Huerta AA, Tordera P, Cercos AC, Yuste AL, Lopez-Tendero P, Reynes G.** Toxic epidermal necrolysis associated with interleukin-2. *Ann Pharmacother* 2002; **36** (7–8): 1171–4
- 89 **Fossa SD.** Interferon in metastatic renal cell carcinoma. *Semin Oncol* 2000; **27**: 187–93
- 90 **Pyrhonen S, Salminen E, Ruutu M et al.** Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. *J Clin Oncol* 1999; **17**: 2859–67
- 91 **Pyrhonen SO.** Systemic therapy in metastatic renal cell carcinoma. *Scand J Surg* 2004; **93**: 156–61
- 92 **Interferon-alpha and survival in metastatic renal carcinoma.** Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. *Lancet* 1999; **353**: 14–7
- 93 **Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE.** Interferon alfa-2a in advanced renal cell carcinoma. treatment results and survival in 159 patients with long-term follow-up. *J Clin Oncol* 1993; **11**: 1368–75
- 94 **Heinzer H, Huland E, Huland H.** [Regional immunotherapy of metastatic renal cell carcinoma]. *Urologe A* 2002; **41**: 239–48
- 95 **Huland E, Burger A, Fleischer J et al.** Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. *Folia Biol (Praha)* 2003; **49**: 183–90
- 96 **Huland E, Heinzer H, Huland H.** Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). *Anticancer Res* 1999; **19**: 2679–83
- 97 **Rohrmann K, Schleypen J, Adam C, Hofstetter A, Siebels M.** [Complete remission of pulmonary metastasized renal cell carcinoma after inhalative Interleukin-2 therapy.] *Urologe A* 2004; **43** (10): 1271–4
- 98 **Schleypen JS, Von Geldern M, Weiss EH et al.** Renal cell carcinoma infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. *Int J Cancer* 2003; **106**: 905–12
- 99 **Atzpodien J, Korfer A, Palmer PA, Franks CR, Poliwoda H, Kirchner H.** Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha. *Ann Oncol* 1990; **1**: 377–8
- 100 **Atzpodien J, Kirchner H, Illiger HJ et al.** IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma. long-term results of a controlled randomized clinical trial. *Br J Cancer* 2001; **85**: 1130–6
- 101 **Motzer RJ, Murphy BA, Bacik J et al.** Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. *J Clin Oncol* 2000; **18**: 2972–80
- 102 **Negrier S.** Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. *J Clin Oncol* 2004; **22**: 1174–6
- 103 **Negrier S, Escudier B, Lasset C et al.** Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. *N Engl J Med* 1998; **338**: 1272–8
- 104 **Negrier S, Escudier B, Gomez F et al.** Prognostic

- factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. *Ann Oncol* 2002; **13**: 1460-8
- 105 **Motzer RJ, Bacik J, Mazumdar M.** Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. *Clin Cancer Res* 2004; **10**: 6302S-3S
- 106 **Motzer RJ, Bacik J, Schwartz LH et al.** Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. *J Clin Oncol* 2004; **22**: 454-63
- 107 **Motzer RJ, Mazumdar M.** Predicting survival of patients with metastatic renal cell carcinoma. *Urology* 2004; **43** (Suppl. 3): 135-6
- 108 **Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J.** Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. *J Clin Oncol* 1999; **17**: 2530-40
- 109 **Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al.** Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. *Int J Cancer* 1986; **38**: 489-94
- 110 **Oosterwijk E, Bander NH, Divgi CR et al.** Antibody localization in human renal cell carcinoma. a phase I study of monoclonal antibody G250. *J Clin Oncol* 1993; **11**: 738-50
- 111 **Bleumer I, Knuth A, Oosterwijk E et al.** A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. *Br J Cancer* 2004; **90**: 985-90
- 112 **Jocham D, Richter A, Hoffmann L et al.** Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. *Lancet* 2004; **363**: 594-9
- 113 **Barbuto JA, Ensina LF, Neves AR et al.** Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. *Cancer Immunol Immunother* 2004 [Epub ahead of print]
- 114 **Marten A, Renoth S, Heinicke T et al.** Allogeneic dendritic cells fused with tumor cells. preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. *Hum Gene Ther* 2003; **14**: 483-94
- 115 **Gitlitz BJ, Beldegrun AS, Zisman A et al.** A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. *J Immunother* 2003; **26**: 412-9
- 116 **Fishman MN, Antonia SJ.** Cell-based immune therapy for metastatic renal cancer. *Expert Rev Anticancer Ther* 2003; **3**: 837-49
- 117 **Childs R, Chernoff A, Contentin N et al.** Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med* 2000; **343**: 750-8
- 118 **Childs R, Drachenberg D.** Allogeneic stem cell transplantation for renal cell carcinoma. *Curr Opin Urol* 2001; **11**: 495-502
- 119 **Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J.** Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor cell transplant: evidence for a graft-versus-tumor effect. *J Clin Oncol* 1999; **17**: 2044-9
- 120 **Childs RW, Igarashi T.** The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy. *Exp Nephrol* 2002; **10**: 227-34
- 121 **Drachenberg D, Childs RW.** Allogeneic hematopoietic stem cell transplantation for cytokine refractory renal cell carcinoma. *Cancer Treat Res* 2003; **116**: 213-26
- 122 **Drachenberg D, Childs RW.** Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement. *Urol Clin North Am* 2003; **30**: 611-22
- 123 **Gratwohl A, Baldomero H, Demirel T et al.** Hematopoietic stem cell transplantation for solid tumors in Europe. *Ann Oncol* 2004; **15**: 653-60
- 124 **Hayes-Lattin BM, Maziarz RT, Beer TM.** Allogeneic stem-cell transplantation in renal-cell carcinoma. *Curr Oncol Rep* 2001; **3**: 433-7
- 125 **Hu H, Rini B, Zimmerman T, Gajewski T, Stadler W, Vogelzang N.** Allogeneic stem cell transplantation for metastatic renal cell cancer after nonmyeloablative chemotherapy. Updated results from the University of Chicago. *Proc Am Assoc Cancer Res* 2001: Abstract (781) see: [www.asco.org](http://www.asco.org)
- 126 **Negrier S, Mejean A, Oudard S, Escudier B.** [Metastatic kidney cancer: new therapeutic approaches]. *Prog Urol* 2002; **12**: 703-8
- 127 **Rini B, Zimmerman T, Gajewski T, Stadler W, Vogelzang N.** Allogeneic stem cell transplantation for metastatic renal cell cancer after nonmyeloablative chemotherapy. engraftment rates, toxicity and initial clinical results. *Proc Am Assoc Cancer Res* 2002: Abstract no. 719. see [www.asco.org](http://www.asco.org)
- 128 **Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ.** Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility,

- engraftment, and clinical results. *J Clin Oncol* 2002; **20**: 2017–24
- 129 Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. *J Urol* 2001; **165**: 1208–9
- 130 Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. *J Urol* 2000; **163**: 343–7
- 131 Slaton JW, Inoue K, Perrotte P *et al.* Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. *Am J Pathol* 2001; **158**: 735–43
- 132 Stadler W, Wilding G. Angiogenesis inhibitors in genitourinary cancers. *Crit Rev Oncol Hematol* 2003; **46** (Suppl): S41–7
- 133 Anonymous. Bevacizumab (Avastin). *Med Lett Drugs Ther* 2004; **46**: 47–8
- 134 Motzer R, Rini B, Michaelson D *et al.* SU11248, a novel tyrosin kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. *Proc Am Assoc Cancer Res* 2004; **23**: Abstract 4500
- 135 Strumberg D, Bauer R, Moeller J *et al.* Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor, BAY 43–9006 in patients with solid tumors. *Proc Am Soc Clin Oncol* 2002; **21** (Abstract)
- 136 Ratain M, Flaherty K, Stadler W *et al.* Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). *Proc Am Assoc Cancer Res* 2004; **23**: Abstract 4501, See [www.asco.org](http://www.asco.org)
- 137 Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. *Clin Cancer Res* 2004; **10**: 6367S–70S
- 138 Anonymous. Clinical Trial. <http://www.clinicaltrials.gov> 2004
- 139 Drevs J, Hofmann I, Hugenschmidt H *et al.* Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. *Cancer Res* 2000; **60**: 4819–24
- 140 Foon KA, Yang XD, Weiner LM *et al.* Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. *Int J Radiat Oncol Biol Phys* 2004; **58**: 984–90
- 141 Rowinsky EK, Schwartz GH, Gollob JA *et al.* Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. *J Clin Oncol* 2004; **22**: 3003–15
- 142 Wood JM, Bold G, Buchdunger E *et al.* PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. *Cancer Res* 2000; **60**: 2178–89
- 143 Drucker B, Bacik J, Ginsberg M *et al.* Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. *Invest New Drugs* 2003; **21**: 341–5
- 144 Fukuoka M, Yano S, Giaccone G *et al.* Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2003; **21**: 2237–46

**Korespondence:**

Michael Siebels,  
Urologische Klinik und Poliklinik,  
Ludwig Maximilians University,  
Klinikum Grosshadern,  
Marchioninstr. 15, 81377 Munich,  
Germany.  
e-mail: [michael.siebels@med.uni-muenchen.de](mailto:michael.siebels@med.uni-muenchen.de)

**Zkratky:** WBRT, whole-brain radiation therapy; CRA, 13-*cis*-retinoic acid; DC, dendritic cell; VEGF(R), vascular endothelial growth factor (receptor); EGF, endothelial growth factor; PDGFR, platelet-derived growth factor receptor.